RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the ...

Conversion of a semisolid Ayurvedic preparation (Vasavaleha) to an oral solution (syrup) form and evaluation of its clinical effects on patients with bronchial asthma. Xia & He Publishing Inc. Journal ...

Scientific Posters on Display Perosphere will feature two posters among the 32 total on display at the conference, including the oral presentation poster and a poster describing the evaluation of ...

“EFFECTS OF EB613 TABLETS [ORAL PTH(1-34)] ON TRABECULAR AND CORTICAL BONE USING 3D-DXA: POST-HOC RESULTS FROM PHASE 2 STUDY” will be presented as an Oral Presentation Friday April 11 at 10:00 ...

Entera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual Meeting ...

supporting further clinical evaluation. TNX-801 also serves as an orthopoxvirus vaccine platform that can deliver multiple protective antigens against diverse viral pathogens. A copy of the ...

The oral presentation will take place on May 10, 2024 in the Targeted Gene and Cell Therapy session, co-chaired by Adicet Bio’s Chief Scientific Officer, Blake Aftab, Ph.D.

PART 1 Oral cavity, pharynx and esophagus. GI Motility online (2006) doi:10.1038/gimo28 Published 16 May 2006. Endoscopic evaluation of oral and pharyngeal phases of swallowing ...

RemeGen Co. Ltd.("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, recently gave an oral presentation on an interim analysis of the evaluation of the ...